Beneficial effects of tamarind trypsin inhibitor in chitosan–whey protein nanoparticles on hepatic injury induced high glycemic index diet: a preclinical study

• Autor(a) principal: Morais, Ana Heloneida de Araujo
• Data de Publicação: 2021
• Outros Autores: Aguiar, Ana J. F. C., Queiroz, Jaluza L. C. de, Santos, Pedro P. A., Camillo, Christina S., Serquiz, Alexandre C., Costa, Izael S., Oliveira, Gerciane S., Gomes, Ana F. T., Matias, Lídia L. R., Costa, Rafael O. A., Passos, Thaís S.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/54482; https://doi.org/10.3390/ijms22189968
• topic: Nanoencapsulation; protease inhibitor; hyperglycemia

Several studies have sought new therapies for obesity and liver diseases. This study investigated the effect of the trypsin inhibitor isolated from tamarind seeds (TTI), nanoencapsulated in chitosan and whey protein isolate (ECW), on the liver health status of the Wistar rats fed with a high glycemic index (HGLI) diet. The nanoformulations without TTI (CW) and ECW were obtained by nanoprecipitation technique, physically and chemically characterized, and then administered to the animals. The adult male Wistar rats (n = 20) were allocated to four groups: HGLI diet + water; standard diet + water; HGLI diet + ECW (12.5 mg/kg); and HGLI diet + CW (10.0 mg/kg), 1 mL per gagave, for ten days. They were evaluated using biochemical and hematological parameters, Fibrosis 4 Index for Liver Fibrosis (FIB-4), AST to Platelet Ratio Index (APRI) scores, and liver morphology. Both nanoparticles presented spherical shape, smooth surface, and nanometric size [120.7 nm (ECW) and 136.4 nm (CW)]. In animals, ECW reduced (p < 0.05) blood glucose (17%), glutamic oxalacetic transaminase (39%), and alkaline phosphatase (24%). Besides, ECW reduced (p < 0.05) APRI and FIB-4 scores and presented a better aspect of hepatic morphology. ECW promoted benefits over a liver injury caused by the HGLI diet